Using MRI and CT to Evaluate Tumor Response in Esophageal Cancer Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of magnetic resonance imaging (MRI) compared to conventional CT simulation in assessing tumor response and defining target volumes for patients with esophageal or esophagogastric cancer undergoing chemoradiotherapy. Patients will undergo both MRI and CT scans before treatment, after 18-22 fractions of therapy, and post-treatment to evaluate changes in tumor characteristics. The study aims to establish predictive models based on imaging features to improve treatment planning and patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma, adenocarcinoma of the esophageal or esophagogastric junction
* Unresectable or potentially resectable tumor (cT3-4N0-1M0-M1a, according to AJCC 6th) based on standard primary staging by EUS and CT
* Age\>18 years
* No distant metastasis other than supraclavicular lymph nodes
* No prior history of thoracic radiation or chemotherapy
* Patients must have normal organ and marrow function as defined below: Leukocytes: greater than or equal to 3,500 G/L; Platelets: greater than or equal to 100,000/mm3 .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit; Creatinine within normal upper limits
* Informed consent

Exclusion Criteria:

* Contraindication for MRI scanning
* Patients with other cancer history except cervical carcinoma in situ and non-malignant melanoma skin cancer
* Pregnant or lactating females
* Contraindication for radiotherapy or chemotherapy

Where it's running

• Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
  Beijing, China Recruiting

Study contacts

• Study coordinator: Xin Wang, MD
• Email: beryl_wx2000@163.com
• Phone: +861013311583220

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chemoradiotherapy for esophageal and esophagogastric junction cancer

  This study is testing a new combination of chemotherapy, radiation, and immune therapies to see if it helps people with advanced esophageal or esophagogastric junction cancer live longer and feel better.

  Recruiting at 5 sites Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Anyang, Henan and 4 other locations · NCT04821778

• Personalized Ultrafractionated Stereotactic Radiotherapy with Perioperative FLOT for GEJ and Esophageal Cancer

  This trial tests adding a personalized, ultra-fractionated radiotherapy boost (PULSAR) to standard perioperative FLOT chemotherapy for patients with esophageal or gastroesophageal junction cancer to see if it can be used safely.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07700420

• Preventing nausea and vomiting during multi-cycle chemo and immunotherapy in esophageal and lung cancer

  This study tests a combination antiemetic with dexamethasone to see if it lowers nausea and vomiting in adults with esophageal or lung cancer receiving several cycles of chemo plus immunotherapy.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07617246

• Ivonescimab plus FOLFOX for advanced HER2-negative stomach and gastroesophageal junction adenocarcinoma

  This study tests whether adding ivonescimab to standard FOLFOX chemotherapy helps people with advanced, HER2-negative stomach or gastroesophageal junction adenocarcinoma as first-line treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Santa Monica, California and 1 other locations · NCT07070466

• AI prediction of response to pre-surgery chemoimmunotherapy for esophageal cancer

  This project tests whether combining clinical records, CT scans, pathology, and lab results with deep learning can predict which patients with locally advanced esophageal cancer will respond to neoadjuvant chemoimmunotherapy before surgery.

  Recruiting Central South University · Changsha, Hunan · NCT07063901

• 18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers

  We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.

  Recruiting Peking University First Hospital · Beijing · NCT07039474

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.